1-3 of 3
Edward B. Perkins, MD, PhD
Close
Sort by
Journal Articles

Venetoclax and Cytarabine in AML Transformed from Myelofibrosis

John McKay, DO, Matthew Gayhart, MD, Taha Al-Juhaishi, MD, Victor Yazbeck, MD, Edward B. Perkins, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5140.
https://doi.org/10.1182/blood-2019-129429
Published: 2019
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Prithviraj Bose, MD, Daniel M Sullivan, MD, Rachid Baz, MD, Mary Beth Tombes, RN, Ellen Shrader, Viswanathan Ramakrishnan, PhD, Wen Wan, PhD, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD
Journal: Blood
Blood (2012) 120 (21): 2959.
https://doi.org/10.1182/blood.V120.21.2959.2959
Published: 2012
Journal Articles

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Lubomir Sokol, MD, PhD, Kristy L. Richards, PhD, MD, Samir Parekh, MD, Rebecca Elstrom, MD, Ashraf Z. Badros, MD, Igor Espinoza-Delgado, MD, Michael J. Schell, PhD, Amy Kimball, MD, PhD, Mary Beth Tombes, RN, Ellen Shrader, Heidi Sankala, PhD, Domenico Coppola, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, John D. Roberts, MD, Steven Grant, MD
Journal: Blood
Blood (2011) 118 (21): 779.
https://doi.org/10.1182/blood.V118.21.779.779
Published: 2011